Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

Intellia Therapeutics (NTLA) stock plummets after the company's Q3 updates indicate a patient deeath in a Phase 3 for its nex ...

A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse ...

Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.

Intellia Therapeutics stock crashed Friday after a patient in its gene-editing study died following serious increases in liver enzymes.

Intellia Therapeutics faces a pivotal moment as the biotech firm prepares to release third-quarter financial results. While the company is scheduled to present Q3 figures on Thursday, investor ...

Vivo is rolling out OriginOS 6, based on Android 16, starting in early November 2025. This update promises enhanced performance, smoother animations, and AI integration with Google Gemini. The rollout ...

One of the pioneers of in vivo cell therapy, Umoja Biopharma, has cleared another regulatory milestone after getting a fast-track designation from the FDA for its lead candidate for blood cancers, ...

Love a Vivo phone but need to stay within budget? We've handpicked the best Vivo smartphones under 20000 that offer the perfect balance of quality, features, and affordability. Whether it’s ...

Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.